Study on Pembrolizumab with Belzutifan and Lenvatinib, or Pembrolizumab/Quavonlimab with Lenvatinib, Compared to Pembrolizumab and Lenvatinib for Advanced Kidney Cancer

Inclusion Criteria

• Diagnosed with kidney cancer that has a clear cell component.
• Have not received any previous treatment for advanced clear cell kidney cancer.
• Male participants must agree to use birth control or abstain from sex during the study and for at least 7 days after the last dose of belzutifan and lenvatinib.
• Female participants must not be pregnant or breastfeeding and must use effective birth control or abstain from sex during the study and for a specified time after the last dose of the study drugs.
• Blood pressure must be well-controlled, with or without medication.
• Must have good organ function.
• If receiving bone-strengthening therapy, it must have started at least 2 weeks before joining the study.

Exclusion Criteria

• Have another cancer that is getting worse or needed treatment in the last 3 years.
• Had major surgery, except kidney removal, within 4 weeks before starting the study.
• Have cancer that has spread to the brain or spinal cord.
• Received radiation therapy within 2 weeks before starting the study.
• Have low oxygen levels or need oxygen therapy.
• Have serious heart disease within the last year.
• Have a history of lung disease.
• Have fluid around the lungs that causes symptoms, unless stable after treatment.
• Have abnormal connections between organs or tissues.
• Have a weakened immune system or are taking medications that suppress the immune system.
• Have mental health or substance abuse issues that would interfere with the study.
• Received a live vaccine within 30 days before starting the study.
• Have an active autoimmune disease needing treatment in the last 2 years.
• Have a history of lung inflammation needing steroids or current lung inflammation.
• Have an active infection needing treatment.
• Have a history of HIV or Hepatitis B.
• Have tumors affecting major blood vessels.
• Have had significant bleeding in the last 3 months.
• Have had a tissue or organ transplant.